Literature DB >> 31481901

Red Blood Cell Membrane Processing for Biomedical Applications.

Luigia Rossi1,2, Alessandra Fraternale1, Marzia Bianchi1, Mauro Magnani1,2.   

Abstract

Red blood cells (RBC) are actually exploited as innovative drug delivery systems with unconventional and convenient properties. Because of a long in vivo survival and a non-random removal from circulation, RBC can be loaded with drugs and/or contrasting agents without affecting these properties and maintaining the original immune competence. However, native or drug-loaded RBC, can be modified decorating the membrane with peptides, antibodies or small chemical entities so favoring the targeting of the processed RBC to specific cells or organs. Convenient modifications have been exploited to induce immune tolerance or immunogenicity, to deliver antibodies capable of targeting other cells, and to deliver a number of constructs that can recognize circulating pathogens or toxins. The methods used to induce membrane processing useful for biomedical applications include the use of crosslinking agents and bifunctional antibodies, biotinylation and membrane insertion. Another approach includes the expression of engineered membrane proteins upon ex vivo transfection of immature erythroid precursors with lentiviral vectors, followed by in vitro expansion and differentiation into mature erythrocytes before administration to a patient in need. Several applications have now reached the clinic and a couple of companies that take advantage from these properties of RBC are already in Phase 3 with selected applications. The peculiar properties of the RBC and the active research in this field by a number of qualified investigators, have opened new exciting perspectives on the use of RBC as carriers of drugs or as cellular therapeutics.

Entities:  

Keywords:  RBC carriers; RBC circulation; RBC membrane modifications; RBC targeting; drug targeting

Year:  2019        PMID: 31481901      PMCID: PMC6710399          DOI: 10.3389/fphys.2019.01070

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


  59 in total

1.  Preparation and characterization of 'heparinocytes': erythrocytes with covalently bound low molecular weight heparin.

Authors:  M Müller; L Büchi; K Woodtli; A Haeberli; J H Beer
Journal:  FEBS Lett       Date:  2000-02-25       Impact factor: 4.124

2.  In vitro targeting of erythrocytes to cytotoxic T-cells by coupling of Thy-1.2 monoclonal antibody.

Authors:  L Chiarantini; R Droleskey; M Magnani; J R DeLoach
Journal:  Biotechnol Appl Biochem       Date:  1992-04       Impact factor: 2.431

3.  Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation.

Authors:  M Magnani; U Mancini; M Bianchi; A Fazi
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

4.  Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Kristina Danielyan; Juan-Carlos Murciano; Kumkum Ganguly; Tatiana Krasik; Ronald P Taylor; Steven Pincus; Steven Jones; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

Review 5.  CR1 and CR1-like: the primate immune adherence receptors.

Authors:  D J Birmingham; L A Hebert
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

6.  Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.

Authors:  S Dominici; M E Laguardia; G Serafini; L Chiarantini; C Fortini; A Tripiciano; E Brocca-Cofano; A Scoglio; A Caputo; V Fiorelli; R Gavioli; A Cafaro; B Ensoli; M Magnani
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

7.  Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies.

Authors:  M Magnani; L Rossi; G Brandi; G F Schiavano; M Montroni; G Piedimonte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

8.  Erythrocytes deliver Tat to interferon-gamma-treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro.

Authors:  Silvia Corinti; Laura Chiarantini; Sabrina Dominici; Maria Elena Laguardia; Mauro Magnani; Giampiero Girolomoni
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

9.  ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement.

Authors:  Dirk Spitzer; Jacqueline Unsinger; Monica Bessler; John P Atkinson
Journal:  Mol Immunol       Date:  2004-02       Impact factor: 4.407

10.  Red blood cells as an antigen-delivery system.

Authors:  M Magnani; L Chiarantini; E Vittoria; U Mancini; L Rossi; A Fazi
Journal:  Biotechnol Appl Biochem       Date:  1992-10       Impact factor: 2.431

View more
  10 in total

1.  Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.

Authors:  Apb Balaji; Srinivasan Bhuvaneswari; D Nanda Kumar
Journal:  Med Hypotheses       Date:  2020-06-07       Impact factor: 1.538

2.  In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2.

Authors:  Magnus A G Hoffmann; Collin Kieffer; Pamela J Bjorkman
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-10       Impact factor: 6.698

3.  Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice.

Authors:  Katarina Blagovic; Carolyne K Smith; Amritha Ramakrishnan; Lindsay Moore; David R Soto; Zachary Thompson; Adam P Stockmann; Sonia Kruszelnicki; Akshi Thakkar; Jason Murray; Sebastian Torres; Bersabel Wondimagegnhu; Roslyn Yi; Maisam Dadgar; Abdul M Paracha; Claire Page; Louise Clear; Omer A Chaudhry; Melissa Myint; Devin T Bridgen; Jonathan B Gilbert; Katherine J Seidl; Armon Sharei; Scott Loughhead; Howard Bernstein; Defne Yarar
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

4.  Recent advances in cell membrane-camouflaged nanoparticles for inflammation therapy.

Authors:  Rongtao Zhang; Siqiong Wu; Qian Ding; Qingze Fan; Yan Dai; Shiwei Guo; Yun Ye; Chunhong Li; Meiling Zhou
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 5.  Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.

Authors:  Luigia Rossi; Francesca Pierigè; Mattia Paolo Aliano; Mauro Magnani
Journal:  BioDrugs       Date:  2020-06       Impact factor: 5.807

6.  Dual-Target Peptide-Modified Erythrocyte Membrane-Enveloped PLGA Nanoparticles for the Treatment of Glioma.

Authors:  Yuexin Cui; Jiejie Sun; Wenyan Hao; Mengyu Chen; Yingzi Wang; Fenghua Xu; Chunsheng Gao
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

Review 7.  Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!

Authors:  Jerard Seghatchian; Jason P Acker; Jeffery S Putter
Journal:  Transfus Apher Sci       Date:  2020-09-03       Impact factor: 1.764

8.  Cell-mediated targeting drugs delivery systems.

Authors:  Hongli Yu; Zhihong Yang; Fei Li; Lisa Xu; Yong Sun
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 9.  Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers.

Authors:  Giulia Della Pelle; Nina Kostevšek
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 10.  Polymeric Nanoparticles Properties and Brain Delivery.

Authors:  Laís Ribovski; Naomi M Hamelmann; Jos M J Paulusse
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.